Objectives: To model the standard broth microdilution method, based on a modified Gompertz function, to obtain accurate vancomycin MIC values for methicillin-resistant Staphylococcus aureus (MRSA). The effect of these MIC values on the vancomycin therapeutic target of AUC 0 -24 /MIC ≥400 was evaluated.
Introduction
The efficacy of vancomycin treatment in patients with methicillinresistant Staphylococcus aureus (MRSA) infection is associated with an area under the concentration -time curve to MIC ratio [AUC 0 -24 (mg . h/L)/MIC (mg/L)] of ≥400. 1 In patients infected with MRSA strains with vancomycin MIC values .1 mg/L, poor clinical results are obtained after vancomycin standard dosage therapy. In addition, the bacteraemia duration and recurrence, hospitalization and mortality rates are directly proportional to vancomycin MIC values. 2, 3 In these clinical trials, the correlation with poor outcomes is primarily based on MIC values determined by the agar diffusion method with antibiotic concentration gradient strips (Etest; bioMérieux, Marcy-l'Étoile, France), which is not the reference method, although it is approved by the American Society for Microbiology and European Society for Clinical Microbiology and Infectious Diseases.
Therefore, to achieve an optimal value of AUC 0 -24 /MIC ≥400 is relevant to predicting good clinical outcomes in MRSA infections and changes in the vancomycin MIC value due to the method used for its determination could also be very relevant.
The standard microdilution method 4 involves a semi-quantitative test, which gives an approximation of the lowest concentration of antibiotic required to prevent microbial visible growth. The range of antibiotic concentrations used for MIC determination involves log 2 vancomycin dilutions from 8 to 0.016 mg/L.
The standard microdilution method has a recognized accuracy of one dilution interval; therefore, for MIC values of 1 mg/L, this method accepts variations between 0.5 and 2 mg/L. Thereby, the differences found in the vancomycin MIC values obtained by Etest and microdilution can be due to the inherent variability of the latter, so it would be highly desirable to develop a method to achieve a more accurate determination of MICvalues by the microdilution method.
Lambert and Pearson 5 described a non-linear regression model for the MIC determination of disinfectants using values obtained by the microdilution method. The MIC, in that model, is defined mathematically based on a Gompertz function modified to fit the data of the reference method (MIC ¼10
, where B is a slope parameter and M is the log concentration of the inflection point).
The aim of this study was to adapt Lambert and Pearson's mathematical model 5 to obtain more accurate vancomycin MIC values for MRSA isolates by the microdilution method and to evaluate its influence on the pharmacodynamic therapeutic target of AUC 0 -24 /MIC ≥400.
Methods
Three MRSA clinical isolates (119049, 119731 and 119000) with vancomycin MICs of 1, 1.5 and 2 mg/L, respectively, as determined by Etest (bioMér-ieux, France), were used to determine the vancomycin MIC by the broth microdilution method, with log 2 dilutions ranging from 8 to 0.016 mg/L, according to CLSI recommendations, 6 and a second MIC determination using log 2 dilutions ranging from 6 to 0.02 mg/L to mimic the concentrations used by the Etest method.
The microdilution plates were incubated at 378C in air for 24 h and then the optical density of each well, at 600 nm (OD 600 ), was determined with a spectrometer plate reader (UVM-340; ASYS Hitech, Austria). The MIC was determined in triplicate for each bacterial isolate and S. aureus ATCC 29213 was used as quality control strain.
The OD 600 values were modelled using a modified non-linear regression method based on an F-test (GraphPad Prism 5.0). 7 OD 600 data (bacterial growth) were adjusted by the Gompertz equation to calculate the MIC and confidence intervals (CIs) directly, and were not based on the inflection point.
The mean vancomycin AUC 0 -24 obtained for a 30 mg/kg/day dosing schedule was calculated using a Monte Carlo simulation over 5000 subjects through an application built in Microsoft w Excel, in which the AUC 0 -24 (mg . h/L) was calculated as daily dose/total clearance (D 24h /CL). The vancomycin pharmacokinetic (PK) parameters included in this model were derived from a previous study in our hospital. 8 It was assumed that all the population PK parameters were distributed as a log-normal function.
Results
The modelling curves and MIC values are shown in Figure 1 . The mean AUC 0 -24 derived from the Monte Carlo simulation was 441.4+149.2 mg . h/L (90% CI 437.3 -445.6 mg . h/L).
The MIC values (mg/L) and their 90% CIs as well as the pharmacodynamic parameter (PD) AUC 0 -24 /MIC for each strain, clinical and control, are shown in Table 1 .
Discussion
Our results show that vancomycin MICvalues obtained by the broth microdilution standard method are lower than those obtained by Etest, as previously described when these two techniques were compared. 9, 10 This fact does not seem to affect the optimal therapeutic ratio of AUC 0 -24 /MIC ≥400 in strains with MICs of ≤1 mg/L by Etest. However, in those strains where MIC values are .1 mg/L, this PD ratio could not be obtained due to the CIs found for AUC 0 -24 /MIC including values ,400.
Although a low number of isolates was used, this model considered the inherent variability of the microdilution method for MIC determinations, which could explain the differences found in clinical outcomes after vancomycin treatment of MRSA infections due to strains with Etest vancomycin MIC values of 1. The low correlation between the two susceptibility testing methods for prediction of the therapeutic response in these vancomycin-treated infections 11 can be explained by these data. Finally, this method provides a mathematical approach to determine the exact value of the MIC by the standard microdilution method that allows a more accurate adjustment of the PK/PD parameters for vancomycin treatment of severe MRSA infections. However, randomized clinical trials are needed to elucidate the clinical utility of this new methodology for MIC determinations. Lepe et al.
